Y27632是一种具有细胞渗透性的ROCK抑制剂,能选择性的抑制ROCK1(p160ROCK)和ROCK2。
CAS: 129830-38-2
纯度:>98%
保存:-20 °C避光保存。
货号 | 产品名称 | 规格 | 纯度 | 品牌 |
ALX-270-333-M025 | Y-27632 . dihydrochloride | 25 mg | >98% | ENZO(美国) |
ALX-270-333-M005 | Y-27632 . dihydrochloride | 5 mg | >98% | ENZO(美国) |
ALX-270-333-M001 | Y-27632 . dihydrochloride | 1 mg | >98% | ENZO(美国) |
文献引用
-----------------------------------------------------------------------------------------------------------------------------
1. The effect of ROCK on TNF-α-induced CXCL8 secretion by intestinal epithelial cell lines is mediated through MKK4 and JNK signaling:
A.C. Perey, et al.; Cell Immunol. 293, 80 (2015), Application(s): Cell Culture, Abstract;
2. Dissecting the roles of ROCK isoforms in stress-induced cell detachment. : J. Shi, et al. ; Cell Cycle 12, 1492,1500 (2013),Abstract;
3. Distinct roles for ROCK1 and ROCK2 in the regulation of cell detachment: J. Shi, et al.; Cell Death Dis. 4, e483 (2013),Abstract; Full Text;
4. Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells. : FA. Suprynowicz, et al. ; PNAS 109, 20035,20040 (2012),
Abstract;
5. ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial Cells : X. Liu, et al.; Am. J. Pathol. 180, 599,607 (2012),
Abstract;
6. Use of reprogrammed cells to identify therapy for respiratory papillomatosis. : H. Yuan, et al. ; N Engl J Med 367, 1220,1227 (2012), Abstract;
7. Small molecule inhibition of cytoskeletal dynamics in melanoma tumors results in altered transcriptional expression patterns of key genes
involved in tumor initiation and progression: C. Spencer, et al.; Cancer Genom. Proteom. 8, 77 (2011), Abstract;
8. Effects of rho-kinase inhibition on pulmonary hypertension, lung growth, and structure in neonatal rats chronically exposed to hypoxia. : AJ. Ziino,
et al.; Pediatr Res. 67, 177,82 (2010), Abstract;
9. The proline-rich region of HIV-1 Nef affects CXCR4-mediated chemotaxis in Jurkat T cells: C.M. Lee, et al.; Viral Immunol. 21, 347 (2008), Abstract;
10. A Rho-kinase inhibitor, Y-27632, reduces cholinergic contraction but not neurotransmitter release: L. Fernandes, et al.; Eur. J. Pharmacol. 550,
155 (2006), Abstract;
11. Molecular characterization of the effects of Y-27632: H. Darenfed, et al.; Cell Motil. Cytoskeleton (2006), Abstract;
12. Rho-kinase inhibitor, Y-27632, has an antinociceptive effect in mice: K. Buyukafsar, et al.; Eur. J. Pharmacol. 541, 49 (2006),Abstract;
13. Structural basis for induced-fit binding of Rho-kinase to the inhibitor Y-27632: H. Yamaguchi, et al.; J. Biochem (Tokyo) 140, 305 (2006), Abstract;
14. Preventive effect of Y-27632, a selective Rho-kinase inhibitor, on ischemia/reperfusion-induced acute renal failure in rats: K. Teraishi, et al.;
Eur. J. Pharmacol. 505, 205 (2004), Abstract;
15. Comparison of effects of Y-27632 and Isoproterenol on release of cytokines from human peripheral T cells: M. Aihara, et al.; Int. Immunopharmacol.
3, 1619 (2003), Abstract;
16. Inhibition of high K+-induced contraction by the ROCKs inhibitor Y-27632 in vascular smooth muscle: possible involvement of ROCKs in a signal
transduction pathway: K. Sakamoto, et al.; J. Pharmacol. Sci. 92, 56 (2003), Abstract;
17. Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity: C. Breitenlechner, et al.;
Structure 11, 1595 (2003), Abstract;
18. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells: R.W. Rees, et al.; J. Urol.
170, 2517 (2003), Abstract;
19. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway: K. Chitaley, et al.; Nat. Med. 7, 119 (2001),
Abstract;
20. Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632: M. Takamura,
et al.; Hepatology 33, 577 (2001), Abstract;
21. A p160ROCK-specific inhibitor, Y-27632, attenuates rat hepatic stellate cell growth: H. Iwamoto, et al.; J. Hepatol. 32, 762 (2000), Abstract;
22. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases: T. Ishizaki, et al.; Mol. Pharmacol. 57, 976 (2000), Abstract;
23. Specificity and mechanism of action of some commonly used protein kinase inhibitors: S.P. Davies, et al.; Biochem. J. 351, 95 (2000), Abstract; Full Text
24. The effect of a Rho kinase inhibitor Y-27632 on superoxide production, aggregation and adhesion in human polymorphonuclear leukocytes: A. Ka
waguchi, et al.; Eur. J. Pharmacol. 403, 203 (2000), Abstract;
25. Use and properties of ROCK-specific inhibitor Y-27632: S. Narumiya, et al.; Meth. Enzymol. 325, 273 (2000), Abstract;
26. Y-27632, an inhibitor of rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase: F. Ima
mura, et al.; Jpn. J. Cancer Res. 91, 811 (2000), Abstract;
27. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase: M. Maekawa, et al.; Science 285, 895 (1999), Abstract;
28. Molecular dissection of the Rho-associated protein kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma N1E-115 cells: M. Hirose, et al.;
J. Cell Biol. 141, 1625 (1998), Abstract;
29. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension: M. Uehata, et al.; Nature389, 990 (1997), Abstract;